Answers are grounded in this paper and cite their sources.
Background The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib shows marked therapeutic efficacy for EGFR -mutated non–small cell lung cancer (NSCLC). Clinical indicators of the survival benefit for first-line treatment with osimertinib have not been identified, however. Methods A retrospective analysis of medical records was performed for 68 NSCLC patients who received osimertinib as first-line treatment between August 2018 and January 2025 and who achieved a complete response (CR), a partial response (PR), or stable disease (SD). Results Progression-free survival (PFS) did not differ significantly between patients with a CR or PR and those with SD (median of 24.2 versus 22.2 months, respectively, P = 0.91). Although no significant correlation was apparent between maximum tumor shrinkage and PFS (R = 0.11, P = 0.52), the size of the residual primary tumor at maximum shrinkage was significantly correlated with PFS (R = –0.34, P = 0.04). PFS was numerically longer in patients with a primary tumor diameter of ≤2 cm at maximum shrinkage than in those with a corresponding diameter of >2 cm (median of 26.6 versus 18.2 months, P = 0.24). The former individuals also showed lower rates of emergence of new lesions (16.7% versus 42.3%) and worsening of extrathoracic lesions (0% versus 57.6%) at disease progression. Conclusion A small size of the primary tumor at maximum shrinkage may be an optimal surrogate for favorable efficacy of osimertinib as fist-line treatment for EGFR -mutated NSCLC, and may be associated with suppressed metastatic potential of the disease.
No takes yet. Share an insight, caveat, or question.
Nagase et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: